Analytical Data
-
Gene name
PDE3B
- Application
-
Alternative Names
cGMP-inhibited 3'.5'-cyclic phosphodiesterase 3B. EC:3.1.4.17. CGIPDE1. CGIP1. Cyclic GMP-inhibited phosphodiesterase B. CGI-PDE B
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13370
-
Expression Region
401-500 aa
-
AA Sequence
LTPFPGFYPCSEIEDPAEKGDRKLNKGLNRNSLPTPQLRRSSGTSGLLPVEQSSRWDRNNGKRPHQEFGISSQGCYLNGPFNSNLLTIPKQRSSSVSLTH
-
Molecular Weight
36.74 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Phosphodiesterase 3B (PDE3B) is an important enzyme that plays a crucial role in regulating cellular levels of cyclic AMP (cAMP) and cyclic GMP (cGMP), which are vital secondary messengers involved in various physiological processes, including lipid metabolism, insulin signaling, and cardiac function. Dysregulation of PDE3B activity has been implicated in various metabolic disorders, such as obesity, type 2 diabetes, and cardiovascular diseases. Consequently, PDE3B has emerged as a promising target for therapeutic interventions aimed at these conditions. Research efforts have focused on the recombinant production of PDE3B protein to enable detailed biochemical studies, structural characterization, and high-throughput screening of potential inhibitors. The ability to produce active PDE3B in a recombinant system allows scientists to investigate its enzymatic properties, elucidate the mechanisms of its regulation, and explore its interactions with other signaling molecules. Understanding the structure-function relationship of PDE3B through crystallography and other biophysical techniques could aid in the rational design of specific inhibitors, paving the way for novel treatments for diseases associated with altered cAMP/cGMP signaling pathways. The ongoing exploration of PDE3B as a therapeutic target underscores its relevance in drug development and highlights the importance of recombinant protein research in advancing our understanding of complex biochemical pathways.











